Antibodies News and Research

RSS

Novel low-cost immunotherapy for cancer cells

Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others.

8 Jan 2009

New nasal spray vaccine shown to be effective against botulism

A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy .

8 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Antibodies take 'evolutionary leaps' to fight microbes

With cold and flu season in full swing, the fact that viruses and bacteria rapidly evolve is apparent with every sneeze, sniffle, and cough.

5 Jan 2009

PDL BioPharma and Alexion Pharmaceuticals resolve patent dispute

PDL BioPharma, Inc. and Alexion Pharmaceuticals, Inc. today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized antibody, Soliris (eculizumab) and PDL's patents known as the Queen et al. patents.

5 Jan 2009

Magnetic nanotags allow sensitive detection of cancer biomarkers

The detection of cancer-associated proteins, or biomarkers, in blood samples is a potentially powerful tool for early diagnosis of cancer and monitoring of cancer treatment.

29 Dec 2008

New therapy for transplant rejection

Researchers in the U.S. have discovered a new cancer drug which effectively treats transplant rejections.

29 Dec 2008

FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin's lymphomas

The U.S. Food and Drug Administration has approved Mozobil (plerixafor), a drug that helps increase the number of blood stem cells for bone marrow transplantation in patients with certain forms of blood cancer.

18 Dec 2008

Human parechovirus may trigger type 1 diabetes

Human parechovirus is a harmless virus which is encountered by most infants and displays few symptoms.

18 Dec 2008

Gold nanowires zap cancer

The next big thing in cancer treatment may be hotter, covered in more gold, and even be a better swimmer than recent Olympic champion Michael Phelps.

18 Dec 2008

Researchers solve failed vaccine mystery

Research led by Johns Hopkins Children's Center scientists has figured out why a respiratory syncytial virus vaccine used in 1966 to inoculate children against the infection instead caused severe respiratory disease and effectively stopped efforts to make a better one.

15 Dec 2008

Researchers develop universal influenza vaccine for animals

A University of Maryland-led science team has developed a universal influenza vaccine for animals that may help prevent or delay another human flu pandemic.

14 Dec 2008

FDA to review Barr Pharmaceutical's BLA for adenovirus type 4 and 7 live oral vaccines

Barr Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review Duramed Pharmaceuticals, Inc.'s Adenovirus Types 4 and 7 Live Oral Vaccines Biologics License Application (BLA).

14 Dec 2008

Researchers identify how key mutations occur in human lymphomas

Researchers at the Keck School of Medicine of the University of Southern California (USC) have explained how certain key mutations occur in human lymphomas - a process that has, until now, remained a mystery.

12 Dec 2008

Novavax announces positive results in trial of seasonal influenza VLP (trivalent) vaccine candidate

Novavax, Inc. has announced favorable results from a Phase IIa human clinical trial of its seasonal influenza VLP (trivalent) vaccine candidate.

12 Dec 2008

Enzyme that mutates antibodies also targets cancer-causing gene

The human immune system is in a perpetual state of self-experimentation. It expertly mutates and shuffles the DNA of its own cells to evolve new defenses against the vast array of microbes that try to invade our bodies.

12 Dec 2008

Enzyme that mutates antibodies also targets a cancer-causing oncogene

Rockefeller University scientists have discovered that the same enzyme that enables the immune system's defensive creativity is also responsible for a particular genetic malfunction - a translocation of one piece of DNA to the wrong chromosome - that causes Burkitt's lymphoma.

12 Dec 2008

Mathematical models of adaptive immunity

More than five million people die every year from infectious diseases, despite the availability of numerous antibiotics and vaccines. The discovery of penicillin to treat bacterial infections, along with the development of vaccines for previously incurable virus diseases such as polio and smallpox, achieved great reductions in mortality during the mid-20th century.

11 Dec 2008

An enzyme that mutates antibodies also targets a cancer-causing oncogene

11 Dec 2008

Blocking immune receptor molecule improves response to HIV-like virus, prolongs survival in monkeys

By blocking PD-1 (programmed death-1), an immune receptor molecule known to inhibit the immune response to chronic viral infections, scientists have safely and significantly reduced the plasma viral load and also prolonged survival of rhesus macaque monkeys severely infected with simian immunodeficiency virus (SIV), the nonhuman primate version of human immunodeficiency virus (HIV).

10 Dec 2008